Article Information
History
- July 31, 2024.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Hannah Lukeman1,2,3,
- Hareth Al-Wassiti4,
- Stewart A. Fabb4,
- Leonard Lim4,
- Trixie Wang2,
- Warwick J. Britton2,5,
- Megan Steain1,3,
- Colin W. Pouton4,
- James A. Triccas1,2,3,* and
- Claudio Counoupas1,2,3,*
- 1Sydney Infectious Diseases Institute (Sydney ID) and School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW, 2006, Australia
- 2Centre for Infection and Immunity, Centenary Institute, The University of Sydney, Camperdown, NSW, 2006, Australia
- 3Charles Perkins Centre, The University of Sydney, Camperdown, NSW, 2006, Australia
- 4Monash Institute of Pharmaceutical Sciences, Parkville, Victoria, 3052, Australia
- 5Department of Clinical Immunology, Royal Prince Alfred Hospital, Camperdown, NSW, 2050, Australia
- ↵*Correspondance: jamie.triccas{at}sydney.edu.au; c.counoupas{at}centenary.org.au
Posted July 31, 2024.
A lipid nanoparticle-mRNA vaccine provides potent immunogenicity and protection against Mycobacterium tuberculosis
